AAPL344.63-4.28 (-1.23%) ▼|ABBV294.89+4.10 (+1.41%) ▲|ABT106.20+1.63 (+1.56%) ▲|ACN258.24+11.02 (+4.46%) ▲|ADBE250.23+2.11 (+0.85%) ▲|AMAT390.09-31.57 (-7.49%) ▼|AMD504.80-61.62 (-10.88%) ▼|AMGN466.01+5.28 (+1.15%) ▲|AMT187.78+1.90 (+1.02%) ▲|AMZN240.35-3.44 (-1.41%) ▼|AVGO326.08-18.92 (-5.48%) ▼|AXP319.11-4.60 (-1.42%) ▼|BA171.55-1.10 (-0.64%) ▼|BAC50.01-1.13 (-2.21%) ▼|BKNG148.13-2.30 (-1.53%) ▼|BLK1,147.54-28.70 (-2.44%) ▼|BMY62.48+1.09 (+1.78%) ▲|BNY147.11-2.26 (-1.51%) ▼|BRK-B542.49+0.53 (+0.10%) ▲|C122.64-3.12 (-2.48%) ▼|CAT622.75-24.64 (-3.81%) ▼|CL95.29+2.13 (+2.29%) ▲|CMCSA23.22+0.95 (+4.27%) ▲|COF204.85-3.89 (-1.86%) ▼|COP154.03+4.00 (+2.67%) ▲|COST1,012.28+17.67 (+1.78%) ▲|CRM229.17-1.73 (-0.75%) ▼|CSCO104.51-4.08 (-3.76%) ▼|CVS90.25-0.08 (-0.09%) ▼|CVX235.52+4.06 (+1.75%) ▲|DE675.48+15.48 (+2.35%) ▲|DHR232.23-4.75 (-2.00%) ▼|DIS110.94+0.03 (+0.03%) ▲|DUK127.39+1.49 (+1.18%) ▲|EMR164.94-5.80 (-3.40%) ▼|FDX313.28+5.46 (+1.77%) ▲|GD372.59+1.77 (+0.48%) ▲|GE301.80-11.25 (-3.59%) ▼|GEV857.87-29.98 (-3.38%) ▼|GILD170.68+5.07 (+3.06%) ▲|GM87.40+1.68 (+1.96%) ▲|GOOG278.22-4.10 (-1.45%) ▼|GOOGL279.84-3.98 (-1.40%) ▼|GS894.55-33.18 (-3.58%) ▼|HD329.20+0.22 (+0.07%) ▲|HON218.33-3.81 (-1.72%) ▼|IBM257.81-0.47 (-0.18%) ▼|INTC65.76-26.31 (-28.58%) ▼|INTU341.09+9.90 (+2.99%) ▲|ISRG432.01-16.75 (-3.73%) ▼|JNJ273.20-2.00 (-0.73%) ▼|JPM337.04-6.54 (-1.90%) ▼|KO94.08+1.26 (+1.36%) ▲|LIN514.24+11.09 (+2.20%) ▲|LLY1,417.54+43.84 (+3.19%) ▲|LMT636.95-6.64 (-1.03%) ▼|LOW209.07+1.79 (+0.86%) ▲|LRCX239.11-15.28 (-6.01%) ▼|MA638.01+2.31 (+0.36%) ▲|MCD258.12+0.74 (+0.29%) ▲|MDLZ64.94+2.41 (+3.85%) ▲|MDT96.54-0.57 (-0.59%) ▼|META614.99-9.53 (-1.53%) ▼|MMM174.34-3.02 (-1.70%) ▼|MO78.03+1.28 (+1.67%) ▲|MRK149.52+3.19 (+2.18%) ▲|MS184.30-4.55 (-2.41%) ▼|MSFT521.91-8.23 (-1.55%) ▼|MU884.74-49.53 (-5.30%) ▼|NEE83.71+1.57 (+1.91%) ▲|NFLX62.08+0.03 (+0.05%) ▲|NKE38.67+0.25 (+0.65%) ▲|NOW105.12-4.55 (-4.15%) ▼|NVDA204.64-9.02 (-4.22%) ▼|ORCL130.67-8.89 (-6.37%) ▼|PEP137.34+3.55 (+2.65%) ▲|PFE30.52+0.57 (+1.90%) ▲|PG161.57+0.98 (+0.61%) ▲|PLTR184.11-12.31 (-6.27%) ▼|PM208.79+0.29 (+0.14%) ▲|QCOM164.79-20.62 (-11.12%) ▼|RTX199.80+0.40 (+0.20%) ▲|SBUX103.65-1.86 (-1.76%) ▼|SCHW88.05-1.42 (-1.59%) ▼|SO93.71+0.72 (+0.77%) ▲|SPG217.75+2.03 (+0.94%) ▲|T21.41+0.49 (+2.34%) ▲|TMO697.00-12.18 (-1.72%) ▼|TMUS156.44+9.15 (+6.21%) ▲|TSLA399.81-3.49 (-0.87%) ▼|TXN300.84-10.58 (-3.40%) ▼|UBER65.25-0.49 (-0.75%) ▼|UNH406.97-3.94 (-0.96%) ▼|UNP304.00+2.07 (+0.69%) ▲|UPS108.25+0.92 (+0.86%) ▲|USB59.45-1.19 (-1.96%) ▼|V413.59+3.05 (+0.74%) ▲|VZ44.73+1.07 (+2.45%) ▲|WFC83.40-1.41 (-1.66%) ▼|WMT123.51+2.26 (+1.86%) ▲|XOM187.25+3.96 (+2.16%) ▲|AAPL344.63-4.28 (-1.23%) ▼|ABBV294.89+4.10 (+1.41%) ▲|ABT106.20+1.63 (+1.56%) ▲|ACN258.24+11.02 (+4.46%) ▲|ADBE250.23+2.11 (+0.85%) ▲|AMAT390.09-31.57 (-7.49%) ▼|AMD504.80-61.62 (-10.88%) ▼|AMGN466.01+5.28 (+1.15%) ▲|AMT187.78+1.90 (+1.02%) ▲|AMZN240.35-3.44 (-1.41%) ▼|AVGO326.08-18.92 (-5.48%) ▼|AXP319.11-4.60 (-1.42%) ▼|BA171.55-1.10 (-0.64%) ▼|BAC50.01-1.13 (-2.21%) ▼|BKNG148.13-2.30 (-1.53%) ▼|BLK1,147.54-28.70 (-2.44%) ▼|BMY62.48+1.09 (+1.78%) ▲|BNY147.11-2.26 (-1.51%) ▼|BRK-B542.49+0.53 (+0.10%) ▲|C122.64-3.12 (-2.48%) ▼|CAT622.75-24.64 (-3.81%) ▼|CL95.29+2.13 (+2.29%) ▲|CMCSA23.22+0.95 (+4.27%) ▲|COF204.85-3.89 (-1.86%) ▼|COP154.03+4.00 (+2.67%) ▲|COST1,012.28+17.67 (+1.78%) ▲|CRM229.17-1.73 (-0.75%) ▼|CSCO104.51-4.08 (-3.76%) ▼|CVS90.25-0.08 (-0.09%) ▼|CVX235.52+4.06 (+1.75%) ▲|DE675.48+15.48 (+2.35%) ▲|DHR232.23-4.75 (-2.00%) ▼|DIS110.94+0.03 (+0.03%) ▲|DUK127.39+1.49 (+1.18%) ▲|EMR164.94-5.80 (-3.40%) ▼|FDX313.28+5.46 (+1.77%) ▲|GD372.59+1.77 (+0.48%) ▲|GE301.80-11.25 (-3.59%) ▼|GEV857.87-29.98 (-3.38%) ▼|GILD170.68+5.07 (+3.06%) ▲|GM87.40+1.68 (+1.96%) ▲|GOOG278.22-4.10 (-1.45%) ▼|GOOGL279.84-3.98 (-1.40%) ▼|GS894.55-33.18 (-3.58%) ▼|HD329.20+0.22 (+0.07%) ▲|HON218.33-3.81 (-1.72%) ▼|IBM257.81-0.47 (-0.18%) ▼|INTC65.76-26.31 (-28.58%) ▼|INTU341.09+9.90 (+2.99%) ▲|ISRG432.01-16.75 (-3.73%) ▼|JNJ273.20-2.00 (-0.73%) ▼|JPM337.04-6.54 (-1.90%) ▼|KO94.08+1.26 (+1.36%) ▲|LIN514.24+11.09 (+2.20%) ▲|LLY1,417.54+43.84 (+3.19%) ▲|LMT636.95-6.64 (-1.03%) ▼|LOW209.07+1.79 (+0.86%) ▲|LRCX239.11-15.28 (-6.01%) ▼|MA638.01+2.31 (+0.36%) ▲|MCD258.12+0.74 (+0.29%) ▲|MDLZ64.94+2.41 (+3.85%) ▲|MDT96.54-0.57 (-0.59%) ▼|META614.99-9.53 (-1.53%) ▼|MMM174.34-3.02 (-1.70%) ▼|MO78.03+1.28 (+1.67%) ▲|MRK149.52+3.19 (+2.18%) ▲|MS184.30-4.55 (-2.41%) ▼|MSFT521.91-8.23 (-1.55%) ▼|MU884.74-49.53 (-5.30%) ▼|NEE83.71+1.57 (+1.91%) ▲|NFLX62.08+0.03 (+0.05%) ▲|NKE38.67+0.25 (+0.65%) ▲|NOW105.12-4.55 (-4.15%) ▼|NVDA204.64-9.02 (-4.22%) ▼|ORCL130.67-8.89 (-6.37%) ▼|PEP137.34+3.55 (+2.65%) ▲|PFE30.52+0.57 (+1.90%) ▲|PG161.57+0.98 (+0.61%) ▲|PLTR184.11-12.31 (-6.27%) ▼|PM208.79+0.29 (+0.14%) ▲|QCOM164.79-20.62 (-11.12%) ▼|RTX199.80+0.40 (+0.20%) ▲|SBUX103.65-1.86 (-1.76%) ▼|SCHW88.05-1.42 (-1.59%) ▼|SO93.71+0.72 (+0.77%) ▲|SPG217.75+2.03 (+0.94%) ▲|T21.41+0.49 (+2.34%) ▲|TMO697.00-12.18 (-1.72%) ▼|TMUS156.44+9.15 (+6.21%) ▲|TSLA399.81-3.49 (-0.87%) ▼|TXN300.84-10.58 (-3.40%) ▼|UBER65.25-0.49 (-0.75%) ▼|UNH406.97-3.94 (-0.96%) ▼|UNP304.00+2.07 (+0.69%) ▲|UPS108.25+0.92 (+0.86%) ▲|USB59.45-1.19 (-1.96%) ▼|V413.59+3.05 (+0.74%) ▲|VZ44.73+1.07 (+2.45%) ▲|WFC83.40-1.41 (-1.66%) ▼|WMT123.51+2.26 (+1.86%) ▲|XOM187.25+3.96 (+2.16%) ▲|
10.8 C
New York
Monday, November 2, 2026

Tag: Breakthrough T1D

newsFORsourcecompanycontentinformationreleases1market

Breakthrough T1D Concludes Inaugural Clinical & Research Congress, Highlighting Global Advances in Type 1 Diabetes Research

CRC 2027 Will Take Place in Washington, D.C., October 15-17, 2027PHILADELPHIA, Oct. 12, 2026 /PRNewswire/ -- Breakthrough T1D, formerly JDRF, the leading global type 1...

Breakthrough T1D Celebrates Approval of Tzield for use in Stage 3 Type 1 Diabetes in the US

NEW YORK, June 12, 2026 /PRNewswire/ -- Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, applauds today's decision from the...

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

FDA approves Sanofi's Tzield as first disease-modifying therapy for children 8-17 with stage 3 type 1 diabetes, delaying insulin decline based on PROTECT

Communiqué de presse : Le Tzield de Sanofi approuvé aux États-Unis comme première thérapie modificatrice de la maladie pour les patients récemment diagnostiqués avec...

La FDA approuve le Tzield de Sanofi comme première thérapie modificatrice pour enfants 8-17 ans atteints de diabète type 1 stade 3, retardant le déclin ins

Breakthrough T1D-Authored Paper Paves the Way for Beta Cell Replacement Therapies on the Path to Cures for Type 1 Diabetes

Changes recommended in clinical trial design to include the voice of more people living with type 1 diabetes in evaluating therapy benefits NEW YORK, Aug....

Breakthrough T1D, formerly JDRF, Leads Multi-Stakeholder Summit in Udaipur, India Highlighting Urgent Need for Early Diagnosis, Access to Care, and Stigma Reduction for Type...

NEW YORK, Aug. 5, 2025 /PRNewswire/ -- Breakthrough T1D International, the leading global type 1 diabetes (T1D) research and advocacy organization, in partnership with Friends of...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBreakthrough T1D

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers